What topics does this cannabis study cover?

This study covers research on: Endocannabinoid.

Where was this research published?

Published in Pharmacopsychiatry on June 10, 2026.

Low-dose cannabis works best: What blood tests reveal about medical THC

Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone.

Pharmacopsychiatry • June 10, 2026 • Moderately Relevant

🤖

AI Summary

This groundbreaking systematic review establishes the first therapeutic reference ranges for THC blood concentrations across different medical cannabis formulations. Researchers analyzed 36 clinical studies to determine the optimal THC levels needed to achieve therapeutic effects for various conditions. The findings reveal a striking insight: relatively low THC concentrations—often much lower than recreational doses—are sufficient for medical benefits. For example, pain relief in diabetic neuropathy requires only 15-30 ng/mL THC, eye pressure reduction occurs below 20 ng/mL, and tic symptom improvement happens at just 7.5-10 ng/mL.

Different pharmaceutical forms of medical cannabis show distinct therapeutic windows. Nabiximols (a standardized cannabis spray) requires 1-10 ng/mL THC to treat neuropathic pain and spasticity in multiple sclerosis patients. For chemotherapy-induced nausea, nabilone needs 1-5 ng/mL while dronabinol (synthetic THC) requires 5-15 ng/mL. These findings contrast sharply with recreational cannabis use, where users often achieve "high" effects at 7-29 ng/mL—meaning therapeutic doses may sometimes fall within or below the range that produces intoxication.

The study's most significant implication is that medical cannabis efficacy doesn't require large doses, potentially reducing side effects and improving treatment tolerability. However, the authors emphasize an important caveat: adverse effects can still occur even within these therapeutic ranges, suggesting careful dose titration and monitoring remain essential. This research provides doctors with data-driven guidance for optimizing cannabis-based treatments across multiple conditions, addressing a major gap in medical cannabis practice where dosing has historically been based on trial-and-error rather than pharmacological evidence.

📄 Original Abstract

Medical cannabis, nabiximols, dronabinol and nabilone are used for various medical conditions. Despite their pronounced pharmacokinetic variability and complex concentration-effect relationships, therapeutic drug monitoring recommendations are lacking. We aimed to identify therapeutic reference ranges based on blood concentration-clinical effect relationships. Studies reporting blood concentrations and clinical effects/adverse effects or assessing cannabinoid receptors 1 and 2 occupancy were selected through a systematic literature search in the MEDLINE database via PubMed. Twenty-three articles were selected for vaporized/smoked medical cannabis, three for nabiximols, nine for dronabinol and one for nabilone. No article was identified for delta-9-tetrahydrocannabinol-dominant cannabis extracts. For vaporized/smoked medical cannabis, an orienting therapeutic reference range of 15-30 ng/mL delta-9-tetrahydrocannabinol was identified for pain reduction in diabetic peripheral neuropathy, while concentrations of <20 ng/mL delta-9-tetrahydrocannabinol were significantly correlated with intraocular pressure reduction and 7.5-10 ng/mL with improvement of tic symptoms. Half-maximum effective concentrations of 7-29 ng/mL delta-9-tetrahydrocannabinol were reported for "high" effects. For nabiximols, a preliminary therapeutic reference range of 1-10 ng/mL delta-9-tetrahydrocannabinol was determined for treating neuropathic pain and spasticity in adults with multiple sclerosis. For chemotherapy-induced nausea and vomiting, a preliminary therapeutic reference range of 1-5 ng/mL for nabilone and 5-15 ng/mL delta-9-tetrahydrocannabinol for dronabinol was assessed. In conclusion, relatively low concentrations may be sufficient to achieve therapeutic effects across all substances studied, with medical cannabis demonstrating these effects at lower concentrations than typically observed in recreational use. Nevertheless, adverse effects at therapeutic reference ranges cannot be excluded.

Paper Type

📄 Research

Publication

Journal: Pharmacopsychiatry
Published: June 10, 2026
PMID: 42269696
DOI: 10.1055/a-2853-4984

Authors (9)

Friederike Amann Central Institute of Mental Health, Department of Molecular Neuroimaging, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Gudrun Hefner Society for Neuropsychopharmacology and Pharmacopsychiatry (AGNP), Mannheim, Germany.
Peter Cremer-Schaeffer Bundesopiumstelle, Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany.
Gerhard Gründer Central Institute of Mental Health, Department of Molecular Neuroimaging, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Winfried Häuser Medical Center Pain Medicine and Mental Health Saarbruecken, Saarbruecken, Germany.
+4 more authors